Astria Therapeutics Announces Publication of STAR-0215 Preclinical Data in the Journal of Pharmacology and Experimental Therapeutics
“We were very pleased by our publication in the Journal of Pharmacology and Experimental Therapeutics, further validating the exciting science behind STAR-0215,” said Jill C. Milne, Ph.D., Chief Executive Officer at Astria Therapeutics.
- “We were very pleased by our publication in the Journal of Pharmacology and Experimental Therapeutics, further validating the exciting science behind STAR-0215,” said Jill C. Milne, Ph.D., Chief Executive Officer at Astria Therapeutics.
- STAR-0215 demonstrated potent in vitro inhibition of plasma kallikrein-mediated bradykinin release from high molecular weight kininogen (HWMK) in a physiologically relevant assay.
- The publication can be found at the following link: https://doi.org/10.1124/jpet.123.001740
STAR-0215 is a monoclonal antibody inhibitor of plasma kallikrein in development for the treatment of HAE. - The Phase 1b/2 ALPHA-STAR trial evaluating STAR-0215 in people living with HAE is ongoing, with initial proof-of-concept results from single and multiple dose cohorts expected in mid-2024.